| Year |
Title |
Altmetric |
| 2023
|
Rapid and sustained improvements in GPPGA scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study..
Journal of the American Academy of Dermatology.
2023
|
|
| 2023
|
Hair Oils May Worsen Seborrheic Dermatitis in Black Patients.
Skin Appendage Disorders.
2023
|
|
| 2023
|
Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2).
Dermatology and Therapy.
13:315-328.
2023
|
|
| 2023
|
New Onset Generalized Pustular Psoriasis Rapidly Improved with IL-36 Blockade.
Skin.
7:585-588.
2023
|
|
| 2023
|
Sixty Years of Benzoyl Peroxide Use in Dermatology.
Journal of drugs in dermatology : JDD.
22:54-59.
2023
|
|
| 2023
|
The impact of achieving and maintaining near-complete or complete skin clearance on patient quality of life in moderate-to-severe psoriasis.
Journal of the American Academy of Dermatology.
88:169-172.
2023
|
|
| 2022
|
Outcomes of COVID-19 and Vaccination in Patients with Moderate to Severe Atopic Dermatitis Treated with Tralokinumab.
JAMA Dermatology.
158:1327-1330.
2022
|
|
| 2022
|
A Case of Pityriasis Rosea Following Monkeypox Vaccination.
Skin.
6:523-526.
2022
|
|
| 2022
|
Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis.
British Journal of Dermatology.
187:438-441.
2022
|
|
| 2022
|
The importance of screening for inflammatory bowel disease in patients with psoriasis and psoriatic arthritis.
Indian Journal of Dermatology.
67.
2022
|
|
| 2022
|
Vaccine Toes Are the New COVID Toes.
Skin Appendage Disorders.
8:338-341.
2022
|
|
| 2022
|
Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis.
Dermatology and Therapy.
12:1289-1302.
2022
|
|
| 2022
|
Seborrheic Dermatitis in Older Adults: Pathogenesis and Treatment Options.
Drugs and Aging.
39:315-321.
2022
|
|
| 2022
|
Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis.
Dermatology and Therapy.
12:911-920.
2022
|
|
| 2022
|
Therapeutic Recommendations for the Treatment of Toenail Onychomycosis in the US.
Skin.
6:s31.
2022
|
|
| 2022
|
Erythema Multiforme is Not Always Erythema Multiforme.
Skin.
6:52-55.
2022
|
|
| 2022
|
Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials.
Journal of Dermatological Treatment.
33:261-265.
2022
|
|
| 2021
|
Therapeutic Recommendations for the Treatment of Toenail Onychomycosis in the US.
Journal of drugs in dermatology : JDD.
20:1076-1084.
2021
|
|
| 2021
|
Efficacy of Topical Herbal Anti-inflammatory Treatment (HAT1) for Treating Psoriasis: An Investigator-Initiated Open Label Study.
Journal of drugs in dermatology : JDD.
20:912-913.
2021
|
|
| 2021
|
Common Cutaneous Infections: Patient Presentation, Clinical Course, and Treatment Options.
Medical Clinics of North America.
105:783-797.
2021
|
|
| 2021
|
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial*.
British Journal of Dermatology.
184:1047-1058.
2021
|
|
| 2021
|
Effect of ixekizumab on patient reported outcomes and quality of life in patients with moderate-to-severe plaque psoriasis: 5-year results from the UNCOVER-1 and -2 studies.
Journal of drugs in dermatology : JDD.
20:394-401.
2021
|
|
| 2021
|
Efinaconazole 10% topical solution for the treatment of onychomycosis in pediatric patients: Open-label phase 4 study.
Journal of the American Academy of Dermatology.
84:1140-1142.
2021
|
|
| 2021
|
Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study*.
British Journal of Dermatology.
184:425-436.
2021
|
|
| 2021
|
Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial*.
British Journal of Dermatology.
184:450-463.
2021
|
|
| 2021
|
Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review.
American Journal of Clinical Dermatology.
22:173-192.
2021
|
|
| 2021
|
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of VT-1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail*.
British Journal of Dermatology.
184:270-280.
2021
|
|
| 2021
|
Joint AAD–NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures.
Journal of the American Academy of Dermatology.
84:432-470.
2021
|
|
| 2021
|
Association of Secukinumab Treatment with Tuberculosis Reactivation in Patients with Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis.
JAMA Dermatology.
157:43-51.
2021
|
|
| 2021
|
Treatment-resistant tinea corporis, a potential public health issue.
British Journal of Dermatology.
184:164-165.
2021
|
|
| 2020
|
Improvement of 11 patients with nail psoriasis with apremilast: Results of an investigator-initiated open-label study.
Journal of the American Academy of Dermatology.
83:1830-1832.
2020
|
|
| 2020
|
Topical crisaborole is an efficacious steroid-sparing agent for treating mild-to-moderate seborrhoeic dermatitis.
Journal of the European Academy of Dermatology and Venereology.
34:e809-e812.
2020
|
|
| 2020
|
Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis.
Journal of Dermatological Treatment.
31:763-768.
2020
|
|
| 2020
|
A call for antifungal stewardship.
British Journal of Dermatology.
183:798-799.
2020
|
|
| 2020
|
Treatment-resistant dermatophytosis: A representative case highlighting an emerging public health threat.
JAAD Case Reports.
6:1153-1155.
2020
|
|
| 2020
|
Safety, Pharmacokinetics, and Efficacy of Efinaconazole 10% Topical Solution for Onychomycosis Treatment in Pediatric Patients.
Journal of drugs in dermatology : JDD.
19:867-872.
2020
|
|
| 2020
|
Nail Psoriasis Does Not Affect Skin Response to Ixekizumab in Patients With Moderate-To-Severe Psoriasis.
Journal of drugs in dermatology : JDD.
19:741-746.
2020
|
|
| 2020
|
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
British Journal of Dermatology.
182:1348-1358.
2020
|
|
| 2020
|
Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies.
Journal of the American Academy of Dermatology.
82:1445-1486.
2020
|
|
| 2020
|
Halobetasol 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Males and Females.
Journal of drugs in dermatology : JDD.
19:504-514.
2020
|
|
| 2020
|
Rosacea treatment: a patient-centric approach.
British Journal of Dermatology.
182:1090-1091.
2020
|
|
| 2020
|
Honeycomb-like cavities in a single fingernail plate.
JAAD Case Reports.
6:89-91.
2020
|
|
| 2020
|
Lichen Planopilaris Associated with Spray-on Sunscreen.
Skin.
4:62-63.
2020
|
|
| 2020
|
Secukinumab and Latex Allergies: Don’t Trust Your EMR.
Skin.
4:97-99.
2020
|
|
| 2020
|
Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients.
Journal of the American Academy of Dermatology.
82:161-201.
2020
|
|
| 2019
|
Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial.
Journal of the European Academy of Dermatology and Venereology.
33:2168-2178.
2019
|
|
| 2019
|
Association of psoriasis/psoriatic arthritis with inflammatory bowel disease influences management strategy.
Journal of the European Academy of Dermatology and Venereology.
33:e431-e432.
2019
|
|
| 2019
|
Incidence of serious gastrointestinal events among tildrakizumab-treated patients with psoriasis: Letter to the Editor.
Journal of the European Academy of Dermatology and Venereology.
33:e350-e352.
2019
|
|
| 2019
|
Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy.
Journal of the American Academy of Dermatology.
81:775-804.
2019
|
|
| 2019
|
Itch: an under-recognized problem in psoriasis.
Journal of the European Academy of Dermatology and Venereology.
33:1465-1476.
2019
|
|
| 2019
|
Successful Treatment of Dermatophytomas in 19 Patients Using Efinaconazole 10% Solution.
Skin Appendage Disorders.
5:304-308.
2019
|
|
| 2019
|
Secukinumab provides rapid relief from itching and pain in patients with moderate-to-severe psoriasis: Patient symptom diary data from two phase 3, randomized, placebo-controlled clinical trials.
Acta Dermato-Venereologica.
99:820-821.
2019
|
|
| 2019
|
Treatment of Tinea Capitis.
Skin Appendage Disorders.
5:201-210.
2019
|
|
| 2019
|
Isolated Nail Dystrophy: An Unlikely Presentation of Metastatic Renal Cell Carcinoma.
Skin Appendage Disorders.
5:177-180.
2019
|
|
| 2019
|
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.
Journal of the American Academy of Dermatology.
80:1073-1113.
2019
|
|
| 2019
|
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.
Journal of the American Academy of Dermatology.
80:1029-1072.
2019
|
|
| 2019
|
Subcutaneous panniculitis-like T-Cell lymphoma: A mixed diagnostic approach to diagnosing a vague clinical picture.
Skin.
3:90-97.
2019
|
|
| 2019
|
Lichen Planopilaris in the Setting of Hair Sunscreen Spray.
Skin Appendage Disorders.
5:108-110.
2019
|
|
| 2019
|
How to Manage Onychomycosis.
Skin.
3:1-6.
2019
|
|
| 2019
|
Rapid Access Clinic Expedites Patient Connection with Dermatologic Services and Improves Productivity.
Skin.
3:28-30.
2019
|
|
| 2019
|
Safety of guselkumab in hepatitis B virus infection.
Dermatology Online Journal.
25.
2019
|
|
| 2018
|
Single-Center, Prospective, Blinded Study Comparing the Efficacy and Compatibility of Efinaconazole 10% Solution in Treating Onychomycosis with and without Concurrent Nail Polish Use.
Skin Appendage Disorders.
5:9-12.
2018
|
|
| 2018
|
Subungual Space: The Next Frontier.
Skin Appendage Disorders.
5:50-51.
2018
|
|
| 2018
|
Ungual Horn.
Skin Appendage Disorders.
5:56-59.
2018
|
|
| 2018
|
Is Biotin Safe for Dermatology Patients?.
Skin Appendage Disorders.
4:201.
2018
|
|
| 2018
|
Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials.
Journal of the European Academy of Dermatology and Venereology.
32:1305-1313.
2018
|
|
| 2018
|
Human polyomavirus-7–associated eruption successfully treated with acitretin.
American Journal of Transplantation.
18:1278-1284.
2018
|
|
| 2018
|
Image Gallery: Molluscum contagiosum-like facial lesions in a patient with a renal transplant: deep dermatophytosis due to Trichophyton rubrum.
British Journal of Dermatology.
178:e328.
2018
|
|
| 2018
|
Efinaconazole 10% topical solution: Case review of onychomycosis patients who were completely cured at Week 24.
Skin Appendage Disorders.
4:67-70.
2018
|
|
| 2018
|
Injection site necrosis and ulceration following vaccination in an adult patient.
Journal of drugs in dermatology : JDD.
17:364-367.
2018
|
|
| 2018
|
Safety of secukinumab in hepatitis B virus.
Journal of the European Academy of Dermatology and Venereology.
32:e120-e121.
2018
|
|
| 2018
|
Is severity of disease a prognostic factor for cure following treatment of onychomycosis?.
Journal of drugs in dermatology : JDD.
17:175-178.
2018
|
|
| 2018
|
A phase 2, controlled, dose-ranging study of SB208, an investigational topical nitric oxide-releasing drug, for the treatment of tinea pedis.
Journal of drugs in dermatology : JDD.
17:888-893.
2018
|
|
| 2018
|
Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial.
Journal of the American Academy of Dermatology.
78:90-99.e1.
2018
|
|
| 2017
|
Adalimumab for Nail Psoriasis: Efficacy and Safety from the Open-Label Extension of a Phase-3, Randomized, Placebo-Controlled Trial.
Skin.
1:s97.
2017
|
|
| 2017
|
Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75–89 response: results from two phase 3 studies of secukinumab.
Journal of Dermatological Treatment.
28:492-499.
2017
|
|
| 2017
|
Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis.
Journal of the American Academy of Dermatology.
77:79-87.e1.
2017
|
|
| 2017
|
Greater Efficacy with Secukinumab Treatment is Associated with Greater Psoriasis Symptom Relief: Results from Secukinumab Clinical Trial Data
2017
|
|
| 2017
|
Cutaneous plasmacytosis resembling pityriasis rosea in a 66-year-old white woman: A rare disease presenting in an unusual patient demographic.
JAAD Case Reports.
3:78-81.
2017
|
|
| 2016
|
Optimizing Non-Antibiotic Treatments for Patients with Acne: A Review.
Dermatology and Therapy.
6:555-578.
2016
|
|
| 2016
|
Topical treatment for onychomycosis: Is it more effective than the clinical data suggests?.
The Journal of clinical and aesthetic dermatology.
9:34-39.
2016
|
|
| 2016
|
Response to A financial perspective on the topical treatment of onychomycosis.
Journal of the American Academy of Dermatology.
75:e39.
2016
|
|
| 2016
|
To the Editor.
JAMA Dermatology.
152:848.
2016
|
|
| 2016
|
Onychomycosis: Does cure equate to treatment success?.
Journal of drugs in dermatology : JDD.
15:626-632.
2016
|
|
| 2016
|
Successful Treatment of Paecilomyces lilacinus Onychomycosis with Efinaconazole and Tavaborole..
Skin Appendage Disorders.
1:169-171.
2016
|
|
| 2016
|
Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: Results of two phase 3, randomized, placebo-controlled clinical trials.
International Journal of Dermatology.
55:401-407.
2016
|
|
| 2016
|
Onychomycosis: Strategies to minimize recurrence.
Journal of drugs in dermatology : JDD.
15:279-282.
2016
|
|
| 2016
|
Psychometric validation of the Psoriasis Symptom Diary using Phase III study data from patients with chronic plaque psoriasis.
International Journal of Dermatology.
55:e147-e155.
2016
|
|
| 2016
|
Anti-IL-17 Medications Used in the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review.
American Journal of Clinical Dermatology.
17:33-47.
2016
|
|
| 2016
|
Secukinumab (AIN-457) for the treatment of Psoriasis.
Expert Review of Clinical Pharmacology.
9:187-202.
2016
|
|
| 2016
|
Onychomycosis: Practical Approaches to Minimize Relapse and Recurrence.
Skin Appendage Disorders.
2:83-87.
2016
|
|
| 2015
|
Risk factors and comorbidities for onychomycosis: Implications for treatment with topical therapy.
The Journal of clinical and aesthetic dermatology.
8:38-42.
2015
|
|
| 2015
|
Identifying Signs of Tinea Pedis: A Key to Understanding Clinical Variables.
Journal of drugs in dermatology : JDD.
14:s42-s47.
2015
|
|
| 2015
|
Identifying Signs of Tinea Pedis: A Key to Understanding Clinical Variables..
Journal of drugs in dermatology : JDD.
14:s42-s47.
2015
|
|
| 2015
|
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Results from two randomized, placebo-controlled, phase III trials.
British Journal of Dermatology.
173:949-961.
2015
|
|
| 2015
|
Pulmonary cryptococcosis in the setting of tofacitinib therapy for psoriasis.
Journal of drugs in dermatology : JDD.
14:901-902.
2015
|
|
| 2015
|
Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies.
Journal of the American Academy of Dermatology.
73:62-69.
2015
|
|
| 2015
|
Report of a case of a dermatophytoma successfully treated with topical efinaconazole 10% solution.
Journal of drugs in dermatology : JDD.
14:524-526.
2015
|
|
| 2015
|
The ABCDEF rule: Combining the 'ABCDE rule' and the "ugly duckling sign" in an effort to improve patient self-screening examinations.
The Journal of clinical and aesthetic dermatology.
8:15.
2015
|
|
| 2015
|
A phase 3 randomized, double-blind, vehicle-controlled trial of azelaic acid foam 15% in the treatment of papulopustular rosacea.
Cutis.
96:54-61.
2015
|
|
| 2015
|
Tanning accelerators: Prevalence, predictors of use, and adverse effects.
Journal of the American Academy of Dermatology.
72:99-104.
2015
|
|
| 2014
|
Access of efinaconazole topical solution, 10%, to the infection site by spreading through the subungual space.
Journal of drugs in dermatology : JDD.
13:1394-1398.
2014
|
|
| 2014
|
Treatment of onychomycosis with efinaconazole 10% topical solution and quality of life.
The Journal of clinical and aesthetic dermatology.
7:25-30.
2014
|
|
| 2014
|
A randomized, double-blinded trial evaluating the efficacy and tolerability of vectical ointment (calcitriol 3 mcg/g ointment) when compared to betamethasone diproprionate ointment (64 mg/g) in patients with nail psoriasis.
Journal of drugs in dermatology : JDD.
13:912-915.
2014
|
|
| 2014
|
Erratum: Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies(Journal of the American Academy of Dermatology (2013) 68 (600-8)).
Journal of the American Academy of Dermatology.
70:399.
2014
|
|
| 2014
|
Econazole nitrate foam 1% for the treatment of tinea pedis: Results from two double-blind, vehicle-controlled, phase 3 clinical trials.
Journal of drugs in dermatology : JDD.
13:803-808.
2014
|
|
| 2014
|
Secukinumab in plaque psoriasis - Results of two phase 3 trials.
New England Journal of Medicine.
371:326-338.
2014
|
|
| 2014
|
Tavaborole for the treatment of onychomycosis.
Expert Opinion on Pharmacotherapy.
15:1439-1448.
2014
|
|
| 2014
|
The efficacy and safety of efinaconazole 10% solution for treatment of mild to moderate onychomycosis: A pooled analysis of two phase 3 randomized trials.
Journal of drugs in dermatology : JDD.
13:815-820.
2014
|
|
| 2013
|
To the editor.
JAMA Internal Medicine.
173:2096-2097.
2013
|
|
| 2013
|
Azelaic acid foam 15% in the treatment of papulopustular rosacea: A randomized, double-blind, vehicle-Controlled study.
Cutis.
92:306-317.
2013
|
|
| 2013
|
Treatment of onychomycosis using a submillisecond 1064-nm neodymium:yttrium-aluminum-garnet laser.
Journal of the American Academy of Dermatology.
69:578-582.
2013
|
|
| 2013
|
Item-level psychometric properties for a new patient-reported psoriasis symptom diary.
Value in Health.
16:1014-1022.
2013
|
|
| 2013
|
Efinaconazole 10% solution: A new topical antifungal therapy for onychomycosis.
Expert Review of Dermatology.
8:347-356.
2013
|
|
| 2013
|
Current and emerging options in the treatment of onychomycosis.
Seminars in Cutaneous Medicine and Surgery.
32:S9-S12.
2013
|
|
| 2013
|
Diagnosis, clinical implications, and complications of onychomycosis.
Seminars in Cutaneous Medicine and Surgery.
32:S5-S8.
2013
|
|
| 2013
|
Nail findings board review.
Journal of drugs in dermatology : JDD.
12:705-706.
2013
|
|
| 2013
|
Onychomycosis information for patients..
Seminars in Cutaneous Medicine and Surgery.
32.
2013
|
|
| 2013
|
Program spotlight: The University of Alabama at Birmingham Department of Dermatology Residency Training Program.
Journal of drugs in dermatology : JDD.
12:699-700.
2013
|
|
| 2013
|
Promoting and maintaining or restoring healthy nails: Practical recommendations for clinicians and patients.
Seminars in Cutaneous Medicine and Surgery.
32:S13-S18.
2013
|
|
| 2013
|
Resident Rounds. Part III B: tumor necrosis factor-α antagonists and alopecia areata: a class-wide adverse effect..
Journal of drugs in dermatology : JDD.
12:713-714.
2013
|
|
| 2013
|
The epidemiology, etiology, and pathophysiology of onychomycosis.
Seminars in Cutaneous Medicine and Surgery.
32:S2-S4.
2013
|
|
| 2013
|
Tumor necrosis factor-α antagonists and alopecia areata: A class-wide adverse effect.
Journal of drugs in dermatology : JDD.
12:713-714.
2013
|
|
| 2013
|
Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild-to-moderate toenail onychomycosis: Results from three randomized studies using double-blind vehicle-controlled and open-label active-controlled designs.
Journal of the European Academy of Dermatology and Venereology.
27:287-294.
2013
|
|
| 2013
|
Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies.
Journal of the American Academy of Dermatology.
68:600-608.
2013
|
|
| 2013
|
New side effect of TNF-α inhibitors: Morphea.
SKINmed.
11:59-60.
2013
|
|
| 2013
|
Onchomycosis: an overview..
Journal of drugs in dermatology : JDD.
12.
2013
|
|
| 2013
|
Palmoplantar pustulosis with fulminant dystrophic 20-nail psoriasis in a patient receiving adalimumab therapy.
Journal of drugs in dermatology : JDD.
12:16-17.
2013
|
|
| 2012
|
Cosmetic aspects of nail products and services.
Cosmetic Dermatology -Cedar Knolls-.
25:357-363.
2012
|
|
| 2012
|
Sarcoidosis as an adverse effect of tumor necrosis factor inhibitors.
Journal of drugs in dermatology : JDD.
11:609-612.
2012
|
|
| 2012
|
A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis.
British Journal of Dermatology.
166:389-398.
2012
|
|
| 2011
|
A new classification system for grading the severity of onychomycosis: Onychomycosis severity index.
JAMA Dermatology.
147:1277-1282.
2011
|
|
| 2011
|
Recent updates in oral terbinafine: Its use in onychomycosis and tinea capitis in the US
2011
|
|
| 2011
|
Tinea capitis caused by dermatophytes: A 15-year retrospective study from a Mississippi dermatology clinic.
Cutis.
88:230-233.
2011
|
|
| 2011
|
An open-label study of the safety and efficacy of sertaconazole nitrate in the treatment of seborrheic dermatitis.
Journal of drugs in dermatology : JDD.
10:895-899.
2011
|
|
| 2011
|
Tinea capitis in Birmingham: Survey of elementary school students.
Pediatric Dermatology.
28:476-477.
2011
|
|
| 2011
|
Interest in cosmetic improvement as a marker for tanning behavior: A survey of 1602 respondents.
Journal of Cosmetic Dermatology.
10:3-10.
2011
|
|
| 2011
|
Rosacea - Global diversity and optimized outcome: Proposed international consensus from the Rosacea international expert group.
Journal of the European Academy of Dermatology and Venereology.
25:188-200.
2011
|
|
| 2011
|
Systemic drugs in patients with skin diseases.
Giornale Italiano di Dermatologia e Venereologia.
146:397-424.
2011
|
|
| 2010
|
Chemoprevention of nonmelanoma skin cancer with celecoxib: A randomized, double-blind, placebo-controlled trial
2010
|
|
| 2010
|
Wong type dermatomyositis: 20th case reported.
Journal of drugs in dermatology : JDD.
9:1475-1476.
2010
|
|
| 2010
|
Long-term safety and efficacy of etanercept in patients with psoriasis: An open-label study.
Journal of drugs in dermatology : JDD.
9:928-937.
2010
|
|
| 2010
|
Letters to the editor.
Journal of drugs in dermatology : JDD.
9:750.
2010
|
|
| 2010
|
Naftifine, a topical allylamine..
Journal of drugs in dermatology : JDD.
9:750.
2010
|
|
| 2010
|
Cyclosporine and psoriasis: 2008 National Psoriasis Foundation* Consensus Conference.
Journal of the American Academy of Dermatology.
62:838-853.
2010
|
|
| 2010
|
Optimizing topical therapies for treating psoriasis: a consensus conference..
Cutis.
86.
2010
|
|
| 2010
|
Top-accessed article: White superficial onychomycosis.
JAMA Dermatology.
146:554.
2010
|
|
| 2009
|
Onychomycosis and diabetes.
Journal of the European Academy of Dermatology and Venereology.
23:1119-1122.
2009
|
|
| 2009
|
Safe and effective treatment of seborrheic dermatitis.
Cutis.
83:333-338.
2009
|
|
| 2009
|
Tinea Capitis: Fluconazole in Trichophyton tonsurans Infection.
Pediatric Dermatology.
15:229-232.
2009
|
|
| 2009
|
Lack of classic histology should not prevent diagnosis of necrolytic acral erythema.
Journal of the American Academy of Dermatology.
60:504-507.
2009
|
|
| 2009
|
Results of a National Rosacea Patient Survey: Common issues that concern rosacea sufferers.
Journal of drugs in dermatology : JDD.
8:120-123.
2009
|
|
| 2009
|
An investigator-blind, randomized, 4-week, parallel-group, multicenter pilot study to compare the safety and efficacy of a nonsteroidal cream (Promiseb Topical Cream) and desonide cream 0.05% in the twice-daily treatment of mild to moderate seborrheic dermatitis of the face..
Clinics in Dermatology.
27.
2009
|
|
| 2009
|
Diclofenac sodium 3% gel as a potential treatment for disseminated superficial actinic porokeratosis.
Journal of the European Academy of Dermatology and Venereology.
23:42-45.
2009
|
|
| 2009
|
Rosacea: A review of current topical, systemic and light based therapies.
Giornale Italiano di Dermatologia e Venereologia.
144:673-688.
2009
|
|
| 2008
|
The safety and efficacy of high-dose alefacept compared with a loading dose of alefacept in patients with chronic plaque psoriasis.
SKINmed.
7:67-72.
2008
|
|
| 2008
|
Infliximab for the treatment of severe pustular psoriasis: 6 Years later.
Journal of the European Academy of Dermatology and Venereology.
22:1253-1254.
2008
|
|
| 2008
|
Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis: Results of two randomized, investigator-blinded, multicenter, international, controlled trials*.
Journal of the American Academy of Dermatology.
59:41-54.
2008
|
|
| 2008
|
The prevalence of acne in adults 20 years and older.
Journal of the American Academy of Dermatology.
58:56-59.
2008
|
|
| 2007
|
Reply.
Journal of the American Academy of Dermatology.
57:728.
2007
|
|
| 2007
|
Clayton E. Wheeler Jr.: An Inspiring Teacher.
Journal of Investigative Dermatology.
127:1850.
2007
|
|
| 2007
|
Onychomycosis: Diagnosis and definition of cure.
Journal of the American Academy of Dermatology.
56:939-944.
2007
|
|
| 2007
|
Advances in Topical and Systemic Antifungals.
Dermatologic Clinics.
25:165-183.
2007
|
|
| 2007
|
New opportunities in preventative dermatology: How far should we go?.
Journal of the American Academy of Dermatology.
56:675-676.
2007
|
|
| 2007
|
Percutaneous absorption kinetics of topical metronidazole formulations in vitro in the human cadaver skin model.
Advances in Therapy.
24:239-246.
2007
|
|
| 2007
|
A new gel formulation of miconazole nitrate 2% for the treatment of chronic intertrigo.
Cosmetic Dermatology -Cedar Knolls-.
20:43-44.
2007
|
|
| 2007
|
A novel foam formulation of ketoconazole 2% for the treatment of seborrheic dermatitis on multiple body regions..
Journal of drugs in dermatology : JDD.
6:1001-1008.
2007
|
|
| 2007
|
Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis.
British Journal of Dermatology.
156:138-142.
2007
|
|
| 2007
|
Letter to the editor.
Cutis.
79:57-58.
2007
|
|
| 2007
|
Rosacea trial comparing twice-daily azelaic acid gel 15% with once-daily metronidazole gel 1%..
Cutis.
79:57-58.
2007
|
|
| 2007
|
Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris.
Journal of the American Academy of Dermatology.
56:439.e1-439.e10.
2007
|
|
| 2006
|
Azelaic acid gel 15%: Clinical versatility in the treatment of rosacea.
Cutis.
78:6-19.
2006
|
|
| 2006
|
Azelaic acid gel 15%: clinical versatility in the treatment of rosacea..
Cutis.
78:6-19.
2006
|
|
| 2006
|
Azelaic acid 15% gel for treatment of rosacea.
Expert Review of Dermatology.
1:535-545.
2006
|
|
| 2006
|
A clinical overview of azelaic acid.
Cutis.
77:12-16.
2006
|
|
| 2006
|
Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy.
Journal of Dermatological Treatment.
17:9-17.
2006
|
|
| 2006
|
Intermittent versus continuous terbinafine in the treatment of toenail onychomycosis: A randomized, double-blind comparison.
Journal of Dermatological Treatment.
17:38-44.
2006
|
|
| 2006
|
Alefacept in the treatment of psoriatic nail disease: a proof of concept study..
Journal of drugs in dermatology : JDD.
5:339-340.
2006
|
|
| 2006
|
Efficacy and safety of a new once-daily topical ketoconazole 2% gel in the treatment of seborrheic dermatitis: a phase III trial..
Journal of drugs in dermatology : JDD.
5:646-650.
2006
|
|
| 2006
|
Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial.
Journal of the American Academy of Dermatology.
54.
2006
|
|
| 2005
|
A bipartite interaction between Pseudomonas aeruginosa and fungi in onychomycosis [5].
JAMA Dermatology.
141:1467-1468.
2005
|
|
| 2005
|
A randomized controlled trial assessing the efficacy of fluconazole in the treatment of pediatric tinea capitis.
Journal of the American Academy of Dermatology.
53:798-809.
2005
|
|
| 2005
|
Clinical diagnosis of common scalp disorders..
Journal of Investigative Dermatology Symposium Proceedings.
10:190-193.
2005
|
|
| 2005
|
Modification of the nail psoriasis severity index [8] (multiple letters).
Journal of the American Academy of Dermatology.
53:745-746.
2005
|
|
| 2004
|
Comparison of 15% azelaic acid gel and 0.75% metronidazole gel for the topical treatment of papulopustular rosacea [2] (multiple letters).
JAMA Dermatology.
140:1282-1283.
2004
|
|
| 2004
|
Bioterrorism.
Dermatologic Clinics.
22.
2004
|
|
| 2004
|
The use of 40% urea cream in the treatment of moccasin tinea pedis.
Cutis.
73:355-357.
2004
|
|
| 2004
|
Improvement in nail psoriasis with alefacept.
Journal of the American Academy of Dermatology.
50:p145.
2004
|
|
| 2004
|
Onychotillomania: 2 Case reports.
Cutis.
73:171-174.
2004
|
|
| 2004
|
Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002.
Journal of the American Academy of Dermatology.
50:748-752.
2004
|
|
| 2004
|
Guidelines of care for atopic dermatitis.
Journal of the American Academy of Dermatology.
50:391-404.
2004
|
|
| 2003
|
A Comparison of 15% Azelaic Acid Gel and 0.75% Metronidazole Gel in the Topical Treatment of Papulopustular Rosacea: Results of a Randomized Trial.
JAMA Dermatology.
139:1444-1450.
2003
|
|
| 2003
|
Tinea capitis in adult women masquerading as bacterial pyoderma.
Journal of the American Academy of Dermatology.
49:177-179.
2003
|
|
| 2003
|
Tinea capitis in adult women masquerading as bacterial pyoderma..
Journal of the American Academy of Dermatology.
49:S177-S179.
2003
|
|
| 2003
|
Tinea capitis in Cleveland: Survey of elementary school students.
Journal of the American Academy of Dermatology.
48:189-193.
2003
|
|
| 2003
|
Tinea corporis, tinea cruris, tinea nigra, and piedra.
Dermatologic Clinics.
21:395-400.
2003
|
|
| 2002
|
Cutaneous anthrax management algorithm.
Journal of the American Academy of Dermatology.
47:766-769.
2002
|
|
| 2002
|
Infliximab for the treatment of severe pustular psoriasis [1].
Journal of the American Academy of Dermatology.
47:796-797.
2002
|
|
| 2002
|
Office practice-based confirmation of onychomycosis: A US nationwide prospective survey.
JAMA Internal Medicine.
162:2133-2138.
2002
|
|
| 2002
|
Extrafacial and generalized granulomatous periorificial dermatitis.
JAMA Dermatology.
138:1354-1358.
2002
|
|
| 2002
|
The diagnosis and treatment of nail disorders: Systemic antifungal therapy.
Dermatologic Therapy.
15:78-88.
2002
|
|
| 2002
|
Cutaneous fungal infections in the elderly.
Clinics in Geriatric Medicine.
18:59-75.
2002
|
|
| 2002
|
Reactivity to trichophytin antigen in patients with onychomycosis: Effect of terbinafine.
Journal of the American Academy of Dermatology.
46:371-375.
2002
|
|
| 2001
|
Efficacy and safety of terbinafine 1% solution in the treatment of interdigital tinea pedis and tinea corporis or tinea cruris.
Cutis.
67:261-266.
2001
|
|
| 2001
|
Reply.
Journal of the American Academy of Dermatology.
45:320-321.
2001
|
|
| 2001
|
Guidelines of care for liposuction.
Journal of the American Academy of Dermatology.
45:438-447.
2001
|
|
| 2001
|
Itraconazole pulse therapy is effective and well-tolerated for the treatment of mycotic skin disease.
Todays Therapeutic Trends.
19:1-8.
2001
|
|
| 2001
|
The safety and efficacy of terbinafine in patients with diabetes and patients who are HIV positive..
Cutis.
68:23-29.
2001
|
|
| 2001
|
Tinea capitis of childhood: Incidence and pathogenetic role, of Trichophyton tonsurans in Central Europe [4] (multiple letters) [4].
Journal of the American Academy of Dermatology.
45:320-321.
2001
|
|
| 2000
|
A novel treatment for acne vulgaris and rosacea [2].
Journal of the European Academy of Dermatology and Venereology.
14:423-424.
2000
|
|
| 2000
|
Drug-induced photosensitivity with antimycotics.
Journal of the European Academy of Dermatology and Venereology.
14:444.
2000
|
|
| 2000
|
The diagnosis of nail fungus infection revisited.
JAMA Dermatology.
136:1162-1164.
2000
|
|
| 2000
|
A large-scale North American study of fungal isolates from nails: The frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns.
Journal of the American Academy of Dermatology.
43:641-648.
2000
|
|
| 2000
|
Antifungal drug interactions.
Postgraduate medicine.
107:41-43.
2000
|
|
| 2000
|
Diagnosis and Management of Onychomycosis.
Annals of dermatology.
12:6-8.
2000
|
|
| 2000
|
Erratum: Tinea capitis: A current perspective (Journal of the American Academy of Dermatology (January 2000) 42 (1-20)).
Journal of the American Academy of Dermatology.
42:704.
2000
|
|
| 2000
|
New developments in cutaneous fungal infections.
Current Problems in Dermatology -Chicago then St Louis-.
12:81-85.
2000
|
|
| 2000
|
Onychomycosis: Treatment, quality of life, and economic issues.
American Journal of Clinical Dermatology.
1:19-26.
2000
|
|
| 2000
|
Sex-based professional societies are by no means obsolete - Yet [1].
JAMA Dermatology.
136:553.
2000
|
|
| 2000
|
Tinea capitis: A current perspective.
Journal of the American Academy of Dermatology.
42:1-20.
2000
|
|
| 2000
|
Tinea capitis: A current perspective.
Journal of the American Academy of Dermatology.
42:1-20.
2000
|
|
| 2000
|
Tinea capitis: a current perspective..
Journal of the American Academy of Dermatology.
42:1-20.
2000
|
|
| 1999
|
Antifungal susceptibilities and genetic relatedness of serial Trichophyton rubrum isolates from patients with onychomycosis of the toenail.
1999
|
|
| 1999
|
Asthma induced by allergy to Trichophyton rubrum.
Journal of the European Academy of Dermatology and Venereology.
12:250-253.
1999
|
|
| 1999
|
A full 'cure' for onychomycosis is not always possible [4] (multiple letters).
JAMA Dermatology.
135:852-853.
1999
|
|
| 1999
|
Antifungal susceptibilities and genetic relatedness of serial Trichophyton rubrum isolates from patients with onychomycosis of the toenail
1999
|
|
| 1999
|
British journal of dermatology: Introduction.
British Journal of Dermatology -Supplement-.
141.
1999
|
|
| 1999
|
Novel treatment strategies for superficial mycoses: Introduction.
Journal of the American Academy of Dermatology.
40.
1999
|
|
| 1999
|
Optimal growth conditions for the determination of the antifungal susceptibility of three species of dermatophytes with the use of a microdilution method.
Journal of the American Academy of Dermatology.
40:S9.
1999
|
|
| 1999
|
Safety of itraconazole pulse therapy for onychomycosis. An update..
Postgraduate medicine.
Spec No:17-25.
1999
|
|
| 1999
|
Successful treatment of fluconazole-resistant oropharyngeal candidiasis by a combination of fluconazole and terbinafine.
Clinical and Vaccine Immunology.
6:921-923.
1999
|
|
| 1999
|
Treatment of tinea capitis: Beyond griseofulvin.
Journal of the American Academy of Dermatology.
40.
1999
|
|
| 1999
|
Treatment of tinea pedis when bacterial presence is suspected: A review of the literature.
Todays Therapeutic Trends.
17:159-165.
1999
|
|
| 1999
|
Update on superficial fungal infections. Introduction..
Postgraduate medicine.
Spec No:5.
1999
|
|
| 1998
|
Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail..
Journal of the American Academy of Dermatology.
38:S87-S94.
1998
|
|
| 1998
|
Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail..
Journal of the American Academy of Dermatology.
38:S77-S86.
1998
|
|
| 1998
|
Once-weekly fluconazole in the treatment of onychomycosis: introduction..
Journal of the American Academy of Dermatology.
38:S73-S76.
1998
|
|
| 1998
|
Pharmacokinetics of three doses of once-weekly fluconazole (150, 300, and 450 mg) in distal subungual onychomycosis of the toenail..
Journal of the American Academy of Dermatology.
38:S103-S109.
1998
|
|
| 1998
|
Pharmacokinetics of three once-weekly dosages of fluconazole (150, 300, or 450 mg) in distal subungual onychomycosis of the fingernail..
Journal of the American Academy of Dermatology.
38:S110-S116.
1998
|
|
| 1998
|
Tinea capitis: Fluconazole in trichophyton tonsurans infection.
Pediatric Dermatology.
15:229-232.
1998
|
|
| 1998
|
Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail.
Journal of the American Academy of Dermatology.
38.
1998
|
|
| 1998
|
Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail.
Journal of the American Academy of Dermatology.
38.
1998
|
|
| 1998
|
Once-weekly fluconazole in the treatment of onychomycosis: Introduction.
Journal of the American Academy of Dermatology.
38.
1998
|
|
| 1998
|
Onychomycosis: Pathogenesis, diagnosis, and management.
Clinical Microbiology Reviews.
11:415-429.
1998
|
|
| 1998
|
Pharmacokinetics of three doses of once-weekly fluconazole (150, 300, and 450 mg) in distal subungual onychomycosis of the toenail.
Journal of the American Academy of Dermatology.
38.
1998
|
|
| 1998
|
Pharmacokinetics of three once-weekly dosages of fluconazole (150, 300, or 450 mg) in distal subungual onychomycosis of the fingernail.
Journal of the American Academy of Dermatology.
38.
1998
|
|
| 1997
|
A historical perspective on onychomycosis.
Dermatologic Therapy.
3:43-45.
1997
|
|
| 1997
|
Tinea capitis treatment.
Dermatologic Therapy.
3:79-83.
1997
|
|
| 1997
|
Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial..
Journal of the American Academy of Dermatology.
37:740-745.
1997
|
|
| 1997
|
Trichophyton rubrum Onychomycosis in a 17-Year-Old Girl.
Cutis.
60:253-254.
1997
|
|
| 1997
|
Fungal infections in HIV-infected patients.
Seminars in Cutaneous Medicine and Surgery.
16:200-212.
1997
|
|
| 1997
|
Prevalence of Onychomycosis in Patients Attending a Dermatology Clinic in Northeastern Ohio for Other Conditions.
Archives of Dermatology.
133:1172-1172.
1997
|
|
| 1997
|
Proposed Guidelines for Speakers Discussing Medications and Other Products.
Cutis.
59:271-272.
1997
|
|
| 1997
|
Superficial fungal infections: Errors to avoid in diagnosis and treatment.
Postgraduate medicine.
101:279-287.
1997
|
|
| 1997
|
A higher prevalence of onychomycosis in psoriatics compared with non- psoriatics: A multicentre study.
British Journal of Dermatology.
136:786-789.
1997
|
|
| 1997
|
A multicenter, placebo-controlled, double-blind study of intermittent therapy with itraconazole for the treatment of onychomycosis of the tingemail.
Journal of the American Academy of Dermatology.
36:231-235.
1997
|
|
| 1997
|
Bacterial infection in a patient with onychomycosis.
Journal of the American Academy of Dermatology.
37:493-494.
1997
|
|
| 1997
|
Cardiac arrhythmias associated with coadministration of azole compounds and cisapride [4] (multiple letters).
Clinical Infectious Diseases.
24:1285.
1997
|
|
| 1997
|
Double-blind, randomized comparison of itraconazole capsules vs. placebo in the treatment of toenail onychomycosis.
Cutis.
59:217-220.
1997
|
|
| 1997
|
Large-scale epidemiological study of the causal agents of onychomycosis: Mycological findings from the multicenter onychomycosis study of terbinafine [7].
JAMA Dermatology.
133:1317-1318.
1997
|
|
| 1997
|
One-week therapy with twice-daily butenafine 1% cream versus vehicle in the treatment of tinea pedis: A multicenter, double-blind trial.
Journal of the American Academy of Dermatology.
36.
1997
|
|
| 1997
|
Onychomycosis in children: Prevalence and treatment strategies.
Journal of the American Academy of Dermatology.
36:395-402.
1997
|
|
| 1997
|
Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial.
Journal of the American Academy of Dermatology.
37:740-745.
1997
|
|
| 1997
|
Prevalence of onychomycosis in patients attending a dermatology clinic in Northeastern Ohio for other conditions [3].
JAMA Dermatology.
133:1172-1173.
1997
|
|
| 1997
|
The effect of toenail onychomycosis on patient quality of life.
International Journal of Dermatology.
36:754-756.
1997
|
|
| 1997
|
The use of itraconazole in the treatment of superficial and systemic fungal infections.
Todays Therapeutic Trends.
14:207-224.
1997
|
|
| 1997
|
Treatment of interdigital tinea pedis with a 4-week once-daily regimen of butenafine hydrochloride 1% cream.
Journal of the American Academy of Dermatology.
36.
1997
|
|
| 1997
|
Treatment of tinea capitis with itraconazole.
International Journal of Dermatology.
36:539-541.
1997
|
|
| 1996
|
Comparison of an antifungal agent used alone with an antifungal used with a topical steroid in inflammatory tinea pedis.
Cutis.
58:305-307.
1996
|
|
| 1996
|
Restructuring dermatology education at Cleveland medical centers affiliated with Case Western Reserve University.
JAMA Dermatology.
132:1085-1090.
1996
|
|
| 1996
|
Diagnostic techniques for confirming onychomycosis..
Journal of the American Academy of Dermatology.
35:S6-S9.
1996
|
|
| 1996
|
Intermittent fluconazole dosing in patients with onychomycosis: results of a pilot study..
Journal of the American Academy of Dermatology.
35:216-219.
1996
|
|
| 1996
|
Widespread papules and nodules in a Ugandan man with acquired immunodeficiency syndrome.
JAMA Dermatology.
132:821-826.
1996
|
|
| 1996
|
Reply.
Journal of the American Academy of Dermatology.
35:135.
1996
|
|
| 1996
|
Guidelines of care for superficial mycotic infections of the skin: Pityriasis (tinea) versicolor. Guidelines/Outcomes Committee. American Academy of Dermatology..
Journal of the American Academy of Dermatology.
34:287-289.
1996
|
|
| 1996
|
Guidelines of care for superficial mycotic infections of the skin: tinea capitis and tinea barbae. Guidelines/Outcomes Committee. American Academy of Dermatology..
Journal of the American Academy of Dermatology.
34:290-294.
1996
|
|
| 1996
|
Guidelines of care for superficial mycotic infections of the skin: tinea corporis, tinea cruris, tinea faciei, tinea manuum, and tinea pedis. Guidelines/Outcomes Committee. American Academy of Dermatology..
Journal of the American Academy of Dermatology.
34:282-286.
1996
|
|
| 1996
|
Surgical pearl: nail micronizer..
Journal of the American Academy of Dermatology.
34:278.
1996
|
|
| 1996
|
A U.S. epidemiologic survey of superficial fungal diseases.
Journal of the American Academy of Dermatology.
35:539-542.
1996
|
|
| 1996
|
Clinical pearl: Diagnostic procedures for tinea capitis.
Journal of the American Academy of Dermatology.
34:498-499.
1996
|
|
| 1996
|
Cutaneous Lesions Provide a Clue to Mysterious Pulmonary Process.
JAMA Dermatology.
132:823-824.
1996
|
|
| 1996
|
Cutaneous antifungal therapy in AIDS: Summary of an International Summit.
Infectious Diseases in Clinical Practice.
5:359-370.
1996
|
|
| 1996
|
Cutaneous lesions provide a clue to mysterious pulmonary process. Pulmonary and cutaneous North American blastomycosis infection..
Archives of Dermatology.
132.
1996
|
|
| 1996
|
Cutaneous mycoses in children.
British Journal of Dermatology.
134:7-11.
1996
|
|
| 1996
|
Diagnostic techniques for confirming onychomycosis.
Journal of the American Academy of Dermatology.
35.
1996
|
|
| 1996
|
Guidelines of care for superficial mycotic infections of the skin: Mucocutaneous candidiasis.
Journal of the American Academy of Dermatology.
34:110-115.
1996
|
|
| 1996
|
Guidelines of care for superficial mycotic infections of the skin: Onychomycosis.
Journal of the American Academy of Dermatology.
34:116-121.
1996
|
|
| 1996
|
Guidelines of care for superficial mycotic infections of the skin: Piedra.
Journal of the American Academy of Dermatology.
34:122-124.
1996
|
|
| 1996
|
Intermittent fluconazole dosing in patients with onychomycosis: Results of a pilot study.
Journal of the American Academy of Dermatology.
35:216-219.
1996
|
|
| 1996
|
International summit on cutaneous antifungal therapy, focus on tinea capitis, Boston, Massachusetts, November 11-13, 1994.
Pediatric Dermatology.
13:69-77.
1996
|
|
| 1996
|
Nondermatophyte causes of onychomycosis and superficial mycoses..
Current topics in medical mycology.
7:87-97.
1996
|
|
| 1996
|
Onychomycosis caused by Scytalidium dimidiatum.
Journal of the American Academy of Dermatology.
35:336-338.
1996
|
|
| 1996
|
Surgical pearl: Nail micronizer.
Journal of the American Academy of Dermatology.
34:278.
1996
|
|
| 1996
|
Systemic antifungal drugs and drug interactions [2].
Journal of the American Academy of Dermatology.
35:134-135.
1996
|
|
| 1996
|
Thrombocytopenia caused by fluconazole [4].
Journal of the American Academy of Dermatology.
35:284.
1996
|
|
| 1996
|
Tinea capitis.
Dermatologic Clinics.
14:23-31.
1996
|
|
| 1996
|
Update on the management of onychomycosis: Highlights on the Third Annual International Summit on Cutaneous Antifungal Therapy.
Clinical Infectious Diseases.
23:305-313.
1996
|
|
| 1995
|
Antifungal agents.
Journal of the American Academy of Dermatology.
32:1060.
1995
|
|
| 1995
|
Bonsai tree: Risk factor for disseminated sporotrichosis.
Journal of the American Academy of Dermatology.
33:839-840.
1995
|
|
| 1995
|
Candida as a nail pathogen in healthy patients..
Journal of the Mississippi State Medical Association.
36:379-381.
1995
|
|
| 1995
|
Clinical Pearl: Systemic antifungal drugs and drug interactions.
Journal of the American Academy of Dermatology.
33:259-260.
1995
|
|
| 1995
|
Clinical pearl: Diagnosis of onychomycosis.
Journal of the American Academy of Dermatology.
32:500-501.
1995
|
|
| 1995
|
Cost of therapy for dermatophyte infections.
Journal of the American Academy of Dermatology.
32:1062.
1995
|
|
| 1995
|
Cutaneous involvement with Cryptococcus neoformans in AIDS [4].
Journal of the American Academy of Dermatology.
32:820-821.
1995
|
|
| 1995
|
Failure of clotrimazole-betamethasone dipropionate cream in treatment of Microsporum canis infections.
Journal of the American Academy of Dermatology.
32:1050-1051.
1995
|
|
| 1995
|
Long-term outcome of patients with interdigital tinea pedis treated with terbinafine or clotrimazole.
Journal of the American Academy of Dermatology.
32:290-292.
1995
|
|
| 1995
|
Reply.
Journal of the American Academy of Dermatology.
32:821.
1995
|
|
| 1995
|
Thrombocytopenia caused by fluconazole therapy.
Journal of the American Academy of Dermatology.
32:525-526.
1995
|
|
| 1995
|
Trends in the Management of Cutaneous Fungal Infections.
Medical mycology journal.
36:7-12.
1995
|
|
| 1995
|
Zosteriform zygomycosis.
Journal of the American Academy of Dermatology.
32:357-361.
1995
|
|
| 1994
|
Short-duration therapy for superficial tinea infections [1].
American Family Physician.
49:1349-1350.
1994
|
|
| 1994
|
Cutaneous Antifungal Agents: Selected Compounds in Clinical Practice and Development.
JAMA Dermatology.
130:669-669.
1994
|
|
| 1994
|
Cutaneous involvement with Cryptococcus neoformans in AIDS.
Journal of the American Academy of Dermatology.
30:844-848.
1994
|
|
| 1994
|
Dermatophytes as opportunistic pathogens.
Journal of the American Academy of Dermatology.
30:1021-1022.
1994
|
|
| 1994
|
Introduction: International Summit on Cutaneous Antifungal Therapy.
Journal of the American Academy of Dermatology.
31:S1.
1994
|
|
| 1994
|
Tinea capitis: Itraconazole in Trichophyton tonsurans infection.
Journal of the American Academy of Dermatology.
31:65-67.
1994
|
|
| 1993
|
Therapy of sporotrichosis.
Seminars in Cutaneous Medicine and Surgery.
12:285-289.
1993
|
|
| 1993
|
Malignant fibrous histiocytoma resembling mycetoma..
Journal of the American Academy of Dermatology.
29:318-321.
1993
|
|
| 1993
|
Mechanisms of action of systemic antifungal agents..
Journal of the American Academy of Dermatology.
28:S28-S34.
1993
|
|
| 1993
|
Clinical Pearl: Proximal white subungual onychomycosis in AIDS.
Journal of the American Academy of Dermatology.
29:631-632.
1993
|
|
| 1993
|
Malignant fibrous histiocytoma resembling mycetoma.
Journal of the American Academy of Dermatology.
29:318-321.
1993
|
|
| 1993
|
Mechanisms of action of systemic antifungal agents.
Journal of the American Academy of Dermatology.
28:S28-S34.
1993
|
|
| 1992
|
Antifungal Drug Therapy: A Complete Guide for the Practitioner.
JAMA Dermatology.
128:425-426.
1992
|
|
| 1992
|
Cutaneous blastomycosis.
Cutis.
50:422-424+420.
1992
|
|
| 1992
|
Pyostomatitis vegetans and primary sclerosing cholangitis: Markers of inflammatory bowel disease.
Gastroenterology.
103:668-674.
1992
|
|
| 1991
|
Childhood epidermolysis bullosa acquisita. Report of three cases and review of literature..
Journal of the American Academy of Dermatology.
24:706-714.
1991
|
|
| 1991
|
Childhood epidermolysis bullosa acquisita: Report of three cases and review of literature.
Journal of the American Academy of Dermatology.
24:706-714.
1991
|
|
| 1991
|
Hendersonula toruloidea and Scytalidium hyalinum: Review and Update.
JAMA Dermatology.
127:1041-1044.
1991
|
|
| 1991
|
Pigmented postacne osteoma cutis in a patient treated with minocycline: Report and review of the literature.
Journal of the American Academy of Dermatology.
24:851-853.
1991
|
|
| 1991
|
Rosacea‐Like Lesions due to Familial Mycobacterium avium‐intracellulare Infection.
International Journal of Dermatology.
30:491-497.
1991
|
|
| 1990
|
Does Pityrosporum Ovale Have a Role in Psoriasis?.
JAMA Dermatology.
126:1111-1112.
1990
|
|
| 1989
|
The superficial mycoses and the dermatophytes..
Journal of the American Academy of Dermatology.
21:655-673.
1989
|
|
| 1989
|
The superficial mycoses and the dermatophytes.
Journal of the American Academy of Dermatology.
21:655-673.
1989
|
|
| 1986
|
Reply to Dr. Holdiness.
International Journal of Dermatology.
25:406-406.
1986
|
|
| 1985
|
Eruptive lesions and malignancy..
International Journal of Dermatology.
24:617-629.
1985
|
|
| 1985
|
Eruptive Lesions and Malignancy.
International Journal of Dermatology.
24:617-629.
1985
|
|
| 1983
|
In vivo suppression of neutrophil chemotaxis by systemically and topically administered tetracycline.
Journal of the American Academy of Dermatology.
8:807-812.
1983
|
|
